Rutherford, Matthew AScott, JenniferKarabayas, MairaAntonelou, MarilinaGopaluni, SeerapaniGray, DavidBarrett, JoeBrix, Silke RDhaun, NeerajMcAdoo, Stephen PSmith, Rona MGeddes, Colin CJayne, DavidLuqmani, RaashidSalama, Alan DLittle, Mark ABasu, NeilUK and Ireland Vasculitis Rare Disease Group (UKIVAS)2022-11-152022-11-152021-09-01Rutherford, M A, Scott, J, Karabayas, M, Antonelou, M, Gopaluni, S, Gray, D, Barrett, J, Brix, S R, Dhaun, N, McAdoo, S P, Smith, R M, Geddes, C C, Jayne, D, Luqmani, R, Salama, A D, Little, M A, Basu, N & UK and Ireland Vasculitis Rare Disease Group (UKIVAS) 2021, 'Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19 : A Binational, Registry-Based Cohort Study', Arthritis & Rheumatology, vol. 73, no. 9, pp. 1713-1719. https://doi.org/10.1002/art.417282326-5191PubMedCentral: PMC8251299ORCID: /0000-0002-4206-477X/work/122953880https://hdl.handle.net/2164/195437263608engSDG 3 - Good Health and Well-beingAgedAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapyCOVID-19/mortalityComorbidityFemaleGlucocorticoids/therapeutic useHospitalizationHumansImmunosuppressive Agents/therapeutic useIntensive Care UnitsMaleMiddle AgedOdds RatioOxygen Inhalation Therapy/statistics & numerical dataRegistriesRespiration, Artificial/statistics & numerical dataRespiratory Tract Diseases/epidemiologyRisk FactorsSARS-CoV-2Severity of Illness IndexSystemic Vasculitis/drug therapyR MedicineSupplementary InformationRJournal article10.1002/art.41728739